Vanguard Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Vanguard Capital Management’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.4K	Hold	12,713	–	–	﹤0.01%	3927
2026 Q1	$54.3K	Buy	+12,713	New	+$87K	﹤0.01%	3912

Other funds holding APVO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Vanguard Capital Management's APVO Position: Q2 2026 in Review

Vanguard Capital Management held its Aptevo Therapeutics (APVO) position steady in Q2 2026 at 12,713 shares worth $56.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3927.

Vanguard Capital Management first reported a position in APVO in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold APVO as of Q2 2026.

Vanguard Capital Management held 12,713 shares of Aptevo Therapeutics worth $56.4K as of Q2 2026.
Vanguard Capital Management left its Aptevo Therapeutics share count unchanged in Q2 2026.
Aptevo Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3927 holding.
Vanguard Capital Management first reported a position in Aptevo Therapeutics in Q1 2026 and has held it in 2 quarters since.
9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.